Viatris plant on sale amid restructuring
1 min read . Updated: 14 Dec 2020, 05:23 AM ISTViatris Inc, the entity formed by the merger of Mylan and Pfizer’s arm Upjohn, aims to sell its API-manufacturing plant at Taloja, near Raigad in Maharashtra, and is looking for buyers
NEW DELHI : Viatris Inc., the entity formed by the merger of Mylan and Pfizer’s arm Upjohn, aims to sell its active pharmaceutical ingredient (API)-manufacturing plant at Taloja, near Raigad in Maharashtra, and is looking for buyers. “Viatris today shared with employees its plans to divest its Unit 11 API facility in Taloja, India. The company has initiated a search for a potential buyer," a company spokesperson said on Saturday.
Also read: Why your health plan premium is suddenly spiking
'Tandav' team agrees to change controversial parts after complaints, I&B intervention
2 min read . 09:57 PM IST
Sebamed allowed to use comparative advertising, asked to drop HUL's detergent reference in ads
3 min read . 09:56 PM IST
The Taloja plant, officially called Unit 11, is one of two API facilities in India that would be impacted in a global restructuring of the company following its amalgamation last month and is part of plans to reduce its cost by at least $1 billion by the end of 2024 or sooner, according to the company statement on Saturday.
Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.
